Lark Health raises $55M to expand AI partnerships, reach more patients

Lark Health, a California-based healthcare company that uses AI models for chronic disease prevention, has closed a funding round worth $55 million.

The funding round included contributions from King River Capital and a mix of new and existing investors. In total, Lark has now raised more than $100 million.

The funds are expected to go toward building on current relationships with commercial payers and telehealth providers. The company’s work with Anthem-affiliated health plans, in particular, is expected to prosper as a result of this additional funding.

“Our mission has always been to provide personalized and immediate care driven by AI to people at-risk of chronic conditions, and this new funding and expanded relationship with Anthem are tremendous votes of confidence in Lark’s approach to virtual care,” Lark Health CEO Julia Hu said in a statement. “It is more important than ever before that millions of people at-risk of or managing chronic conditions have access to compassionate care at home, and we are excited to work with innovative commercial payers, telehealth providers, and others to build the future for virtual care.”

According to Lark, more than two million patients already use its platform to access personal counseling for conditions such as diabetes.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.